Plain-English summaries of what published research actually says about commonly tracked peptides — mechanism, evidence, reported risks, and the half-life math that shapes scheduling. Written to inform, not to sell or recommend.
This content summarizes published research and publicly available prescribing information. It is not a substitute for professional medical advice, diagnosis, or treatment, and nothing here is a recommendation to buy or use any compound. Consult a licensed clinician before making any decision about any substance.
A synthetic 15-amino-acid peptide studied mainly in animal models of tendon, ligament, and gut injury — not approved for human use.
An FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes and weight management, backed by large randomized trials.
An FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and weight management, with some of the largest weight-loss effects recorded in trials.
A synthetic peptide based on thymosin beta-4, studied in animal models of tissue repair — not approved for human use.
A two-peptide blend that stimulates the body's own growth-hormone release — studied in small early trials, never approved, and flagged by the FDA.